Association between KSHV genotype and immune response to Kaposi sarcoma

Read full text
Authors: Shohei Yogi, Haruna Ishikawa, Natsuko Yamakawa, Maika Yara, Nobuo Kuninaka, Karina Fonseca Uehara, Yasuka Tanabe, Kiyoto Kurima, Shinichiro Kina, Mika Kina, Kenzo Takahashi, Hirofumi Arakawa
+1 more Takao Kinjo
Cited by: 1
References: 38

Abstract

Kaposi sarcoma (KS) is a locally aggressive endothelial tumor that can be classified into four clinical types: classic, AIDS-related, iatrogenic, and endemic. KS usually affects the skin and soft tissues, but it can develop into mucosal, lymph node, and multiple-organ lesions. KS is caused by Kaposi sarcoma-associated herpes virus (KSHV), which has six genotypes (A, B, C, D, E, and F). However, it remains unclear whether the KSHV genotype affects clinical presentation. In this study, we investigated clinical stage, cellular proliferation, NF-κB activity, and lymphocyte infiltration around the tumor of KS lesions. Additionally, we evaluated the association between the parameters described above and the viral genotypes. Classic KS with genotype C exhibited elevated proliferative activity and most cases progressed to an advanced stage. Lesions in classic KS with genotype C were limited to the skin with high CD4 and CD8 cell infiltration. In contrast, some AIDS-related KS patients with genotype A showed lymph node and visceral involvement and a lower number of immune cells around the tumor, which suggests that host immunity against KSHV affects the clinical presentation. Among patients with AIDS-related KS, the numbers of CD3 and CD8 cells in genotype C were higher than those in genotype A. These results imply that genotype C induces more potent host tumor immunity than genotype A. Thus, the present study suggests that the clinical presentation of KS is associated with both host immunity and KSHV genotypes.

Fields of Study & Subjects

Viral-associated cancers and disorders CNS Lymphoma Diagnosis and Treatment Lymphoma Diagnosis and Treatment

Publication details

Journal / source
Human Pathology
Publisher
Elsevier BV
Volume
172
Pages
106100–106100
Publication date
5 March 2026
Language
EN